Bay 55-9837 (TFA)
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes[1].
Product Specifications
UNSPSC
12352209
Target
GCGR
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/bay-55-9837-tfa.html
Solubility
H2O
Smiles
O=C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC4=CC=C(C=C4)O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC5=CNC=N5)N.OC(C(F)(F)F)=O.[x]
Molecular Formula
C167H270N52O46.xC2HF3O2
Molecular Weight
3742.25 (free base)
References & Citations
[1]Tsutsumi M, et, al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes. 2002 May; 51 (5) : 1453-60.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP11996PU-N 400 µL
UCH37 (UCHL5) (N-term) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
BNC041805-500 1x 500 µL
GP2 (Glycoprotein 2) / ZAP75 (GP2/1805), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
